1,509
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France

, , , , ORCID Icon, , & show all
Pages 205-213 | Received 09 Nov 2021, Accepted 15 Dec 2022, Published online: 05 Jan 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.